Xenon Pharmaceuticals Inc (XENE) Stock Price
XENEStock
$33.49−20.58%52W
Market Cap$3.24B
P/E—
PEG Ratio—
Div yield—
Beta0.09
XENE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-53.48%
Price vs S&P 500 (4W)-12.78%
VGM Score22.02
XENE Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.16 | -$1.11 | +4.41%(+$0.05) | |
| Q1 2026 | -$1.20 | -$1.17 | +2.29%(+$0.03) | |
| Q4 2025 | -$1.21 | -$1.31 | -8.67%(-$0.10) | |
| Q3 2025 | -$1.16 | -$1.15 | +1.23%(+$0.01) | |
| Q2 2025 | -$0.99 | -$1.07 | -8.45%(-$0.08) |
XENE Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.38
4.38
4.38
4.38
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
XENEXenon Pharmaceuticals Inc | D | F | D | 430.4x | — | — | — | $33.49 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals is a biopharmaceutical company developing novel treatments for neurological and psychiatric disorders, including epilepsy, depression, and pain. The company's pipeline includes three epilepsy candidates—XEN1101, NBI-921352, and XEN496—as well as oral Nav1.7 inhibitors for pain management. It targets areas with significant unmet medical need in neuroscience.